Targeted Therapy for Solid Tumors: Current Status

Surgical Oncology Clinics of North America

Volumn 17, Issue 2, 2008, Pages 279-301

  Zureikat, Amer H ^a   McKee, Mark D ^a  

^a UNIVERSITY OF CHICAGO   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTHRACYCLINE; BEVACIZUMAB; CAPECITABINE; CARBOPLATIN; CETUXIMAB; CISPLATIN; CYCLOPHOSPHAMIDE; DOXORUBICIN; ENDOTHELIAL CELL GROWTH FACTOR; ERLOTINIB; FLUOROURACIL; FOLINIC ACID; GEFITINIB; GEMCITABINE; IMATINIB; IMC 225; LAPATINIB; LIGAND; OXALIPLATIN; PACLITAXEL; PANITUMUMAB; PLACEBO; PROTEIN TYROSINE KINASE; SORAFENIB; SUNITINIB; TRASTUZUMAB; UNCLASSIFIED DRUG; VATALANIB; VETCOBIX;

ABDOMINAL PAIN; ACUTE LUNG INJURY; ADJUVANT THERAPY; ANEMIA; ASTHENIA; BINDING SITE; BLEEDING; BONE MARROW ABNORMALITY; BREAST CANCER; CANCER CHEMOTHERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER GROWTH; CANCER RADIOTHERAPY; CANCER SURGERY; CANCER SURVIVAL; CARDIOTOXICITY; CHILL; CLINICAL TRIAL; COLORECTAL CANCER; DERMATITIS; DIARRHEA; DIGESTIVE SYSTEM PERFORATION; DIZZINESS; DOSAGE SCHEDULE COMPARISON; DRUG APPROVAL; DRUG BINDING; DRUG DOSE COMPARISON; DRUG EFFICACY; DRUG HALF LIFE; DRUG SAFETY; DRUG TARGETING; DRUG TOLERABILITY; DRUG WITHDRAWAL; DYSPNEA; EDEMA; EPISTAXIS; FATIGUE; FEVER; GASTROINTESTINAL SYMPTOM; GASTROINTESTINAL TUMOR; GRANULOCYTOPENIA; HAND FOOT SYNDROME; HEAD AND NECK CANCER; HEADACHE; HUMAN; HYPERTENSION; KIDNEY CANCER; LIGAND BINDING; LIVER CELL CARCINOMA; LOW DRUG DOSE; LUNG CANCER; LUNG NON SMALL CELL CANCER; METASTASIS; MOUTH PAIN; MULTIPLE CYCLE TREATMENT; NAUSEA; NEUROLOGIC DISEASE; PANCREAS ADENOCARCINOMA; PANCREAS CANCER; PROTEIN BINDING; PROTEINURIA; PRURITUS; RASH; REVIEW; SIGNAL TRANSDUCTION; SKIN DISCOLORATION; SKIN TOXICITY; SOLID TUMOR; STOMATITIS; THROMBOSIS; TREATMENT RESPONSE; TUMOR CELL; VOMITING;

ANTINEOPLASTIC AGENTS; BREAST NEOPLASMS; COLORECTAL NEOPLASMS; FEMALE; HUMANS; LUNG NEOPLASMS; MALE; NEOPLASMS; PANCREATIC NEOPLASMS; PROTEIN KINASE INHIBITORS; RECEPTOR PROTEIN-TYROSINE KINASES; RECEPTOR, EPIDERMAL GROWTH FACTOR; SIGNAL TRANSDUCTION; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 41049093266     PISSN: 10553207     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.soc.2008.01.004     Document Type: Review

References (70)

1. Normanno N., De Luca A., Bianco C., et al. Epidermal growth factor receptor (EGFR) signaling in cancer. Gene 366 1 (2006) 2-16
2. Salomon D.S., Brandt R., Ciardiello F., et al. Epidermal growth factor-related peptides and their receptors in human malignancies. Crit Rev Oncol Hematol 19 3 (1995) 183-232
3. Grandis J.R., and Sok J.C. Signaling through the epidermal growth factor receptor during the development of malignancy. Pharmacol Ther 102 1 (2004) 37-46
4. Baselga J. Why the epidermal growth factor receptor? The rationale for cancer therapy. Oncologist 7 Suppl 4 (2002) 2-8
5. Huang S.M., Bock J.M., and Harari P.M. Epidermal growth factor receptor blockade with C225 modulates proliferation, apoptosis, and radiosensitivity in squamous cell carcinomas of the head and neck. Cancer Res 59 8 (1999) 1935-1940
6. Mellstedt H. Monoclonal antibodies in human cancer. Drugs Today (Barc) 39 Suppl C (2003) 1-16
7. Yang X.D., Jia X.C., Corvalan J.R., et al. Development of ABX-EGF, a fully human anti-EGF receptor monoclonal antibody, for cancer therapy. Crit Rev Oncol Hematol 38 1 (2001) 17-23
8. Seidman A., Hudis C., Pierri M.K., et al. Cardiac dysfunction in the trastuzumab clinical trials experience. J Clin Oncol 20 5 (2002) 1215-1221
9. Folkman J. Role of angiogenesis in tumor growth and metastasis. Semin Oncol 29 6 Suppl 16 (2002) 15-18
10. Ferrara N. Vascular endothelial growth factor as a target for anticancer therapy. Oncologist 9 Suppl 1 (2004) 2-10
11. Wilhelm S.M., Carter C., Tang L., et al. BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis. Cancer Res 64 19 (2004) 7099-7109
12. Jemal A., Siegel R., Ward E., et al. Cancer statistics, 2007. CA Cancer J Clin 57 1 (2007) 43-66
13. Fukuoka M., Yano S., Giaccone G., et al. Multi-institutional randomized phase II trial of gefitinib for previously treated patients with advanced non-small-cell lung cancer (The IDEAL 1 Trial). [corrected]. J Clin Oncol 21 12 (2003) 2237-2246
14. Kris M.G., Natale R.B., Herbst R.S., et al. Efficacy of gefitinib, an inhibitor of the epidermal growth factor receptor tyrosine kinase, in symptomatic patients with non-small cell lung cancer: a randomized trial. JAMA 290 16 (2003) 2149-2158
15. Inomata S., Takahashi H., Nagata M., et al. Acute lung injury as an adverse event of gefitinib. Anticancer Drugs 15 5 (2004) 461-467
16. Giaccone G., Herbst R.S., Manegold C., et al. Gefitinib in combination with gemcitabine and cisplatin in advanced non-small-cell lung cancer: a phase III trial-INTACT 1. J Clin Oncol 22 5 (2004) 777-784
17. Herbst R.S., Giaccone G., Schiller J.H., et al. Gefitinib in combination with paclitaxel and carboplatin in advanced non-small-cell lung cancer: a phase III trial-INTACT 2. J Clin Oncol 22 5 (2004) 785-794
18. Thatcher N., Chang A., Parikh P., et al. Gefitinib plus best supportive care in previously treated patients with refractory advanced non-small-cell lung cancer: results from a randomised, placebo-controlled, multicentre study (Iressa Survival Evaluation in Lung Cancer). Lancet 366 9496 (2005) 1527-1537
19. Lynch T.J., Bell D.W., Sordella R., et al. Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N Engl J Med 350 21 (2004) 2129-2139
20. Paez J.G., Janne P.A., Lee J.C., et al. EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy. Science 304 5676 (2004) 1497-1500
21. Bell D.W., Lynch T.J., Haserlat S.M., et al. Epidermal growth factor receptor mutations and gene amplification in non-small-cell lung cancer: molecular analysis of the IDEAL/INTACT gefitinib trials. J Clin Oncol 23 31 (2005) 8081-8092
22. Shepherd F.A., Rodrigues Pereira J., Ciuleanu T., et al. Erlotinib in previously treated non-small-cell lung cancer. N Engl J Med 353 2 (2005) 123-132
23. Herbst R.S., Prager D., Hermann R., et al. TRIBUTE: a phase III trial of erlotinib hydrochloride (OSI-774) combined with carboplatin and paclitaxel chemotherapy in advanced non-small-cell lung cancer. J Clin Oncol 23 25 (2005) 5892-5899
24. Gatzemeier U., Pluzanska A., Szczesna A., et al. Phase III study of erlotinib in combination with cisplatin and gemcitabine in advanced non-small-cell lung cancer: the Tarceva Lung Cancer Investigation Trial. J Clin Oncol 25 12 (2007) 1545-1552
25. Tsao M.S., Sakurada A., Cutz J.C., et al. Erlotinib in lung cancer-molecular and clinical predictors of outcome. N Engl J Med 353 2 (2005) 133-144
26. Mattern J., Koomagi R., and Volm M. Association of vascular endothelial growth factor expression with intratumoral microvessel density and tumour cell proliferation in human epidermoid lung carcinoma. Br J Cancer 73 7 (1996) 931-934
27. Sandler A., Gray R., Perry M.C., et al. Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer. N Engl J Med 355 24 (2006) 2542-2550
28. Johnson D.H., Fehrenbacher L., Novotny W.F., et al. Randomized phase II trial comparing bevacizumab plus carboplatin and paclitaxel with carboplatin and paclitaxel alone in previously untreated locally advanced or metastatic non-small-cell lung cancer. J Clin Oncol 22 11 (2004) 2184-2191
29. Fernando N.H., and Hurwitz H.I. Targeted therapy of colorectal cancer: clinical experience with bevacizumab. Oncologist 9 Suppl 1 (2004) 11-18
30. Kabbinavar F., Hurwitz H.I., Fehrenbacher L., et al. Phase II, randomized trial comparing bevacizumab plus fluorouracil (FU)/leucovorin (LV) with FU/LV alone in patients with metastatic colorectal cancer. J Clin Oncol 21 1 (2003) 60-65
31. Hurwitz H., Fehrenbacher L., Novotny W., et al. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med 350 23 (2004) 2335-2342
32. Hurwitz H.I., Fehrenbacher L., Hainsworth J.D., et al. Bevacizumab in combination with fluorouracil and leucovorin: an active regimen for first-line metastatic colorectal cancer. J Clin Oncol 23 15 (2005) 3502-3508
33. Giantonio B.J., Catalano P.J., Meropol N.J., et al. Bevacizumab in combination with oxaliplatin, fluorouracil, and leucovorin (FOLFOX4) for previously treated metastatic colorectal cancer: results from the Eastern Cooperative Oncology Group study E3200. J Clin Oncol 25 12 (2007) 1539-1544
34. Cunningham D., Humblet Y., Siena S., et al. Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer. N Engl J Med 351 4 (2004) 337-345
35. Van Cutsem E., Nowacki M., Lang I., et al. Randomized phase III study of irinotecan and 5-FU/FA with or without cetuximab in the first-line treatment of patients with metastatic colorectal cancer (mCRC): The CRYSTAL trial. 2007 ASCO Annual Meeting Proceedings. Part I. J Clin Oncol 25 Suppl 18S (2007) 4000
36. Van Cutsem E., Peeters M., Siena S., et al. Open-label phase III trial of panitumumab plus best supportive care compared with best supportive care alone in patients with chemotherapy-refractory metastatic colorectal cancer. J Clin Oncol 25 13 (2007) 1658-1664
37. Koehne C., Bajetta E., Lin E., et al. Results of an interim analysis of a multinational randomized, double-blind, phase III study in patients (pts) with previously treated metastatic colorectal cancer (mCRC) receiving FOLFOX4 and PTK787/ZK 222584 (PTK/ZK) or placebo (CONFIRM 2). 2006 ASCO Annual Meeting Proceedings. Part I. J Clin Oncol 24 Suppl 18S (2006) 3508
38. Tyagi P. Vatalanib (PTK787/ZK 222584) in combination with FOLFOX4 versus FOLFOX4 alone as first-line treatment for colorectal cancer: preliminary results from the CONFIRM-1 trial. Clin Colorectal Cancer 5 1 (2005) 24-26
39. Slamon D.J., Clark G.M., Wong S.G., et al. Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science 235 4785 (1987) 177-182
40. Cobleigh M.A., Vogel C.L., Tripathy D., et al. Multinational study of the efficacy and safety of humanized anti-HER2 monoclonal antibody in women who have HER2-overexpressing metastatic breast cancer that has progressed after chemotherapy for metastatic disease. J Clin Oncol 17 9 (1999) 2639-2648
41. Vogel C.L., Cobleigh M.A., Tripathy D., et al. Efficacy and safety of trastuzumab as a single agent in first-line treatment of HER2-overexpressing metastatic breast cancer. J Clin Oncol 20 3 (2002) 719-726
42. Slamon D.J., Leyland-Jones B., Shak S., et al. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med 344 11 (2001) 783-792
43. Robert N., Leyland-Jones B., Asmar L., et al. Randomized phase III study of trastuzumab, paclitaxel, and carboplatin compared with trastuzumab and paclitaxel in women with HER-2-overexpressing metastatic breast cancer. J Clin Oncol 24 18 (2006) 2786-2792
44. Romond E.H., Perez E.A., Bryant J., et al. Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer. N Engl J Med 353 16 (2005) 1673-1684
45. Geyer C.E., Forster J., Lindquist D., et al. Lapatinib plus capecitabine for HER2-positive advanced breast cancer. N Engl J Med 355 26 (2006) 2733-2743
46. Miller K.D., Chap L.I., Holmes F.A., et al. Randomized phase III trial of capecitabine compared with bevacizumab plus capecitabine in patients with previously treated metastatic breast cancer. J Clin Oncol 23 4 (2005) 792-799
47. Michaud D.S. Epidemiology of pancreatic cancer. Minerva Chir 59 2 (2004) 99-111
48. Diaz-Rubio E. New chemotherapeutic advances in pancreatic, colorectal, and gastric cancers. Oncologist 9 3 (2004) 282-294
49. Burris III H.A., Moore M.J., Andersen J., et al. Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial. J Clin Oncol 15 6 (1997) 2403-2413
50. Itakura J., Ishiwata T., Shen B., et al. Concomitant over-expression of vascular endothelial growth factor and its receptors in pancreatic cancer. Int J Cancer 85 1 (2000) 27-34
51. MacKenzie M.J. Molecular therapy in pancreatic adenocarcinoma. Lancet Oncol 5 9 (2004) 541-549
52. Yamanaka Y., Friess H., Kobrin M.S., et al. Coexpression of epidermal growth factor receptor and ligands in human pancreatic cancer is associated with enhanced tumor aggressiveness. Anticancer Res 13 3 (1993) 565-569
53. Ueda S., Ogata S., Tsuda H., et al. The correlation between cytoplasmic overexpression of epidermal growth factor receptor and tumor aggressiveness: poor prognosis in patients with pancreatic ductal adenocarcinoma. Pancreas 29 1 (2004) e1-e8
54. Moore M.J., Goldstein D., Hamm J., et al. Erlotinib plus gemcitabine compared with gemcitabine alone in patients with advanced pancreatic cancer: a phase III trial of the National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol 25 15 (2007) 1960-1966
55. Philip P.A., Benedetti J., Fenoglio-Preiser C., et al. Phase III study of gemcitabine [G] plus cetuximab [C] versus gemcitabine in patients [pts] with locally advanced or metastatic pancreatic adenocarcinoma [PC]: SWOG S0205 study. 2007 ASCO Annual Meeting Proceedings. Part I. J Clin Oncol 25 Suppl 18S (2007) LBA4509
56. Kindler H.L., Niedzwiecki D., Hollis D., et al., Cancer and Leukemia Group B. A double-blind, placebo-controlled, randomized phase III trial of gemcitabine (G) plus bevacizumab (B) versus gemcitabine plus placebo (P) in patients (pts) with advanced pancreatic cancer (PC): a preliminary analysis of Cancer and Leukemia Group B (CALGB). 2007 ASCO Annual Meeting Proceedings. Part I. J Clin Oncol 25 Suppl 18S (2007) 4508
57. Llovet J., Ricci S., Mazzaferro V., et al., SHARP Investigators Study Group. Sorafenib improves survival in advanced hepatocellular carcinoma (HCC): results of a phase III randomized placebo-controlled trial (SHARP trial). 2007 ASCO Annual Meeting Proceedings. Part I. J Clin Oncol 25 Suppl 18S (2007) LBA1
58. Rini B.I., and Small E.J. Biology and clinical development of vascular endothelial growth factor-targeted therapy in renal cell carcinoma. J Clin Oncol 23 5 (2005) 1028-1043
59. Motzer R.J., Hutson T.E., Tomczak P., et al. Sunitinib versus interferon alfa in metastatic renal-cell carcinoma. N Engl J Med 356 2 (2007) 115-124
60. Escudier B., Eisen T., Stadler W.M., et al. Sorafenib in advanced clear-cell renal-cell carcinoma. N Engl J Med 356 2 (2007) 125-134
61. Escudier B., Koralewski P., Pluzanska A., et al., AVOREN investigators. A randomized, controlled, double-blind phase III study (AVOREN) of bevacizumab/interferon-α2a vs placebo/interferon-α2a as first-line therapy in metastatic renal cell carcinoma. 2007 ASCO Annual Meeting Proceedings. Part I. J Clin Oncol 25 Suppl 18S (2007) 3
62. Burtness B., Goldwasser M.A., Flood W., et al. Phase III randomized trial of cisplatin plus placebo compared with cisplatin plus cetuximab in metastatic/recurrent head and neck cancer: an Eastern Cooperative Oncology Group study. J Clin Oncol 23 34 (2005) 8646-8654
63. JB Vermorken. Cetuximab extends survival of patients with recurrent or metastatic SCCHN when added to first line platinum based therapy-results of a randomized phase III (EXTREME) study. 2007 ASCO Annual Meeting Proceedings. Chicago, June 2, 2007.
64. Bonner J.A., Harari P.M., Giralt J., et al. Radiotherapy plus cetuximab for squamous-cell carcinoma of the head and neck. N Engl J Med 354 6 (2006) 567-578
65. Joensuu H., Roberts P.J., Sarlomo-Rikala M., et al. Effect of the tyrosine kinase inhibitor STI571 in a patient with a metastatic gastrointestinal stromal tumor. N Engl J Med 344 14 (2001) 1052-1056
66. Rubin B.P., Singer S., Tsao C., et al. KIT activation is a ubiquitous feature of gastrointestinal stromal tumors. Cancer Res 61 22 (2001) 8118-8121
67. Demetri G.D., von Mehren M., Blanke C.D., et al. Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors. N Engl J Med 347 7 (2002) 472-480
68. Verweij J., Casali P.G., Zalcberg J., et al. Progression-free survival in gastrointestinal stromal tumours with high-dose imatinib: randomised trial. Lancet 364 9440 (2004) 1127-1134
69. National Cancer Institute. A phase III randomized double-blind study of adjuvant imatinib mesylate (Gleevec; STI571) versus placebo in patients following the resection of primary gastrointestinal stromal tumor (GIST).ACOSOG-Z9001. Available at:. http://www.cancer.gov/clinicaltrials/ACOSOG-Z9001 Accessed April 12, 2007
70. Demetri G.D., van Oosterom A.T., Garrett C.R., et al. Efficacy and safety of sunitinib in patients with advanced gastrointestinal stromal tumour after failure of imatinib: a randomised controlled trial. Lancet 368 9544 (2006) 1329-1338